Cue Biopharma (CUE) Share-based Compensation (2017 - 2025)
Cue Biopharma (CUE) posted Share-based Compensation of $610000.0 for Q4 2025, down 60.21% sequentially from $1.5 million in Q3 2025, and down 60.95% YoY from $1.6 million in Q4 2024.
Cue Biopharma (CUE) Share-based Compensation (2017 - 2025) Analysis & Trends
Cue Biopharma has reported Share-based Compensation for 9 years, with the latest figure at $610000.0 in Q4 2025.
- Quarterly Share-based Compensation fell 60.95% year-over-year to $610000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.7 million (down 38.01% YoY) and the FY2025 annual result came in at $4.7 million, down 30.7% from the prior year.
- Share-based Compensation fell to $610000.0 in Q4 2025 per CUE's latest filing, from $1.5 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $23.0 million in Q1 2021 and troughed at $439000.0 in Q4 2022.
- A 5-year average of $7.3 million and a median of $2.1 million in 2023 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2021 and 2023: Share-based Compensation surged 739.86% in 2021, then tumbled 89.22% in 2023.
- Over 5 years, Share-based Compensation stood at $18.1 million in 2021, then slumped by 97.58% to $439000.0 in 2022, then surged by 371.98% to $2.1 million in 2023, then dropped by 24.61% to $1.6 million in 2024, then plunged by 60.95% to $610000.0 in 2025.
- According to Business Quant data, Share-based Compensation over the past three periods registered $610000.0, $1.5 million, and $1.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - | 23.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 610,000.00 |
| Dec 31, 2025 | 610,000.00 |
| Sep 30, 2025 | 1.53 Mn |
| Sep 30, 2025 | 1.53 Mn |
| Jun 30, 2025 | 1.26 Mn |
| Jun 30, 2025 | 1.26 Mn |
| Mar 31, 2025 | 1.34 Mn |
| Mar 31, 2025 | 1.34 Mn |
| Dec 31, 2024 | 1.56 Mn |
| Dec 31, 2024 | 1.56 Mn |
| Sep 30, 2024 | 7.20 Mn |
| Sep 30, 2024 | 7.20 Mn |
| Jun 30, 2024 | 9.20 Mn |
| Jun 30, 2024 | 9.20 Mn |
| Mar 31, 2024 | 1.95 Mn |
| Mar 31, 2024 | 1.95 Mn |
| Dec 31, 2023 | 2.07 Mn |
| Dec 31, 2023 | 2.07 Mn |
| Sep 30, 2023 | 2.07 Mn |
| Sep 30, 2023 | 2.07 Mn |